Abstract:cGAS-cGAMP-STING is essential for sensing foreign DNA from pathogens or self-DNA from dying cancer cells. Activation of this pathway is critical for the innate immune response to cancer and is necessary for the full efficacy of various cancer treatments including checkpoint and PARP inhibitors, radiotherapy, and CAR T-cells. Intense efforts have focused on triggering this pathway with cGAMP analogs, which are small-molecule activators of STING. However, recent reports show that many cancer cells downregulate STING by promoter methylation. Furthermore, T-cells activated by cGAMP undergo apoptosis, which limits the efficacy of T-cells based tumor eradication. Indeed, emerging evidence suggests that the critical cells in which STING activation achieves maximal anti-cancer efficacy is myeloid cells in the tumor microenvironment (TME). saRNAs are small double-stranded complementary RNA oligos that increase target mRNA expression, they directly modulate traditional "undruggable" targets such as STING. Using single cell RNA sequencing data, we demonstrated that STING expression is decreased in myeloid cells within the TME of cancer patients. Therefore, our hypothesis was that saRNAs targeted against STING would restore its expression to levels that are necessary for pathway activation either alone or in combination with other drugs, including cGAMP analogs. Using our proprietary algorithm, we designed saRNA sequences that are complementary to positions +2000 to -2000 nucleotides around the transcriptional start site of STING. The lead sequence (named saSTING) was further optimized by our discovery pipeline. Upregulation of STING mRNA was detected up to 168 hours post-transfection of saSTING in multiple cell lines, with an increase in the range of 4 to 11 fold. The upregulation of STING expression was further validated at the protein level. Strand and sequence specificity of saSTING was demonstrated by mutational analysis. Concerning the mechanism of transcriptional activation via saSTING, we show that saSTING regulates STING expression by increasing both nascent pre-mRNA and mature mRNA. In essence, saSTING causes transcriptional activation across the whole STING locus, which is recapitulated in an upregulation of spliced and polyadenylated (mature) STING mRNA. Development candidate MTL-STING encapsulates saSTING in NOV340 liposomes for in vivo administration. NOV340 liposomes have previously been clinically validated to efficiently deliver saRNA to myeloid cells, which is the critical cellular subset to benefit from STING activation from an anti-tumor perspective. MTL-STING is pre-clinical development as a combination treatment administered intra-tumorally and is expected to enter Phase 1 in 2023. Citation Format: Choon Ping Tan, Konstantina Skourti Stathaki, Brid M Ryan, Valentí Gomez, Laura Sinigaglia, Siv Anita Hegre, Robert Habib, John J Rossi, Nagy A Habib. MTL-STING restores endogenous STING expression for improving efficacy of cancer therapeutics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 382.

A next-generation STING agonist MSA-2: From mechanism to application

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

A novel STING agonist with systemic and durable anti-tumour activity

An orally available non-nucleotide STING agonist with antitumor activity

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

STING, a promising target for small molecular immune modulator: A review

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Design, Synthesis and Biological Evaluation of Acridone Analogues As Novel STING Receptor Agonists

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Agonists and Inhibitors of the STING Pathway: Potential Agents for Immunotherapy

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective

Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)

piSTING: A Pocket‐Independent Agonist Based on Multivalency‐Driven STING Oligomerization

Abstract 382: MTL-STING restores endogenous STING expression for improving efficacy of cancer therapeutics

cGAS-STING pathway in cancer biotherapy

Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy